Transparency Market Research in its new report titled, “Benzodiazepine Anticonvulsant Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026,” provides key insights on the benzodiazepine anticonvulsant drugs market. The TMR report states that the rise in prevalence of seizures across the world will drive the benzodiazepine anticonvulsant drugs market during the forecast period i.e, 2018-2026. According to Healthline Media and Epilepsy Foundation of America, every year, nearly 150,000 people in the U.S. are diagnosed with CNS disorder which causes seizures. Healthline Media also stated that one in 26 people will be diagnosed with seizures in their lifetimes. Epilepsy is defined as having two or more unprovoked seizures. According to the WHO, up to 10% of people across the world have one seizure during their lifetimes. The WHO also stated that nearly 50 million people are living with epilepsy across the globe presently. Every year, between 30 and 50 per 100,000 people are diagnosed with new cases of epilepsy in high-income countries, and this number is two times higher among low and middle income countries, says the report.
The TMR report has segregated the global benzodiazepine anticonvulsant drugs market based on indication, distribution channel, and region. On the basis of terms of indication, the market is bifurcated into generalized seizures and focal (partial) seizures. Generalized seizures can be classified into tonic-clonic seizures, atonic seizures, myoclonic seizures, clonic seizures, and tonic seizures. Focal seizures can be categorized into dyscognitive focal seizures and simple focal seizures. Based on distribution channel, the global benzodiazepine anticonvulsant drugs market can be divided into retail pharmacies, online pharmacies, and hospital pharmacies. On the regional perspective, the global benzodiazepine anticonvulsant drugs market is segmented into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America held the largest market share in 2017, due to new drug launches and increased research and development on benzodiazepine anticonvulsants drugs. Europe held the second largest market share in 2017, owing to increased promotional activities to create awareness regarding the benefits associated with the use of benzodiazepine anticonvulsant drugs in the region.
According to the report, the market in Asia Pacific is anticipated to expand at the fastest growth rate during the forecast period owing to increase in government activities to increase awareness about benzodiazepine anticonvulsants drugs especially in countries such as China and India. Japan held significant market share in Asia Pacific in 2017 owing to high geriatric population in the country. The market in Middle East & Africa and Latin America is anticipated to grow at a moderate pace during the forecast period owing to rise in government initiatives regarding benzodiazepine anticonvulsants drugs in the regions. Some of the key players operating in the global benzodiazepine anticonvulsant drugs market are profiled in this report to give a better competitive analysis and these include F. Hoffmann-La Roche Ltd., MEDA Manufacturing GmbH, Valeant Pharmaceuticals International, Inc., and H. Lundbeck A/S.
About Us
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
